Host: |
Mouse |
Applications: |
IHC-P |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Mouse monoclonal antibody anti-CA19-9 is suitable for use in Immunohistochemistry research applications. |
Clonality: |
Monoclonal |
Clone ID: |
121SLE |
Conjugation: |
Unconjugated |
Isotype: |
IgM |
Formulation: |
Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin |
Purification: |
Affinity purified |
Dilution Range: |
1:100‐200 |
Storage Instruction: |
Store at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C. |
Specificity: |
Positive control: Colon carcinoma |
Immunogen: |
Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B-patient (0Le) |
Background | CA19-9, a carbohydrate epitope expressed on a high MW (>400kDa) mucin glycoprotein, is a sialyl Lewis a structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewis a and/or Lewis b blood group antigens. In normal tissues, sialyl Lewis a antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance